{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-006649","form_type":"8-K","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2025-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.169846+00:00","generated_at":"2026-05-23T03:19:40.429345+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protagenic Therapeutics approves 1-for-14 reverse stock split effective May 5, 2025","bullets":["Reverse stock split at 1-for-14 ratio, effective 12:01 a.m. ET on May 5, 2025.","Intended to bring PTIX into compliance with Nasdaq minimum bid price rule 5550(a)(2).","Share count to drop from ~8.24M to ~588,750; fractional shares rounded up.","Stockholders approved split on April 18, 2025 with ratio range 1:10 to 1:20; board set at 1:14.","Symbol PTIX unchanged; new CUSIP 74365N301; no change in authorized shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-006649","json":"https://secwatch.observer/filing/0001641172-25-006649.json","markdown":"https://secwatch.observer/filing/0001641172-25-006649.md","text":"https://secwatch.observer/filing/0001641172-25-006649.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225006649/0001641172-25-006649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225006649/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T03:19:40.429345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}